Imaging metabolic processes in the body using Carbon-13 pyruvate

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of hyperpolarized Carbon-13 magnetic resonance imaging (MRI) to assess metabolic processes in patients with cardiovascular and cardiometabolic diseases, as well as healthy volunteers. The approach aims to improve upon conventional imaging techniques by providing insights into downstream metabolism without the exposure to ionizing radiation associated with other imaging methods. Participants will receive hyperpolarized 13C-pyruvate to enhance MRI signals, allowing for a more detailed understanding of tissue metabolism. The study will evaluate the feasibility of this innovative imaging technique in a clinical setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Healthy Volunteers:

1. Age 21 years and above
2. No significant medical co-morbidities (such as chronic kidney disease, diabetes mellitus, heart failure, ischemic heart disease, previous strokes)
3. No history of cancer
4. Able and willing to comply with study procedures and provide signed informed consent

Patients with cardiovascular/cardiometabolic diseases:

1. Age 21 years and above
2. Physician diagnosed cardiovascular conditions: ischemic heart disease, inherited cardiomyopathies (hypertrophic, dilated or infiltrative cardiomyopathies) and stable heart failure; and/or
3. Cardiometabolic conditions (such as diabetes on medications, hypertension, central obesity, fatty liver disease)
4. Able and willing to comply with study procedures and provide signed informed consent

Exclusion Criteria:

1. Standard contraindications for magnetic resonance procedures (such as implantable medical devices, suspected presence of surgical apparatus or shrapnel, severe claustrophobia)
2. Unstable medical conditions (such as symptomatic heart failure, unstable hypertension/glucose levels as determined by investigators, symptomatic arrhythmias, angina)
3. Pregnant or nursing women
4. Known allergies to pyruvate or any of its components

Where it's running

• National Heart Centre Singapore
  Singapore, Singapore Recruiting

Study contacts

• Study coordinator: Calvin WL Chin
• Email: CAMI@nhcs.com.sg
• Phone: 6568449055

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biobank of stem cells and biomarkers for cardiovascular disease

  This study is creating a bank of stem cells and blood samples from people with heart disease to help researchers learn more about the condition and find better treatments.

  Recruiting London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario · NCT06371937

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure

  This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.

  Recruiting at 2 sites University Hospital of Cologne · Cologne and 1 other locations · NCT07721649

• Dapagliflozin to Improve Exercise and Heart Function in Fontan Patients

  This study tests whether the diabetes drug dapagliflozin can improve exercise capacity and heart function in people who had a Fontan procedure.

  Recruiting Phase 4 The University of Hong Kong · Hong Kong and 1 other locations · NCT07482943

• Vicadrostat versus spironolactone: effects on kidney function and protein markers

  This will test whether vicadrostat or spironolactone, each given with empagliflozin, changes kidney function and blood/urine protein patterns in adults with CKD and heart disease or heart failure.

  Recruiting at 2 sites Phase 2 University Medical Center Groningen · Groningen, Provincie Groningen and 1 other locations · NCT07304817

• Pulmonary Artery Denervation for a specific type of heart and lung pressure problem

  This study tests whether the Enhancor System can safely and effectively help patients with combined pre- and post-capillary pulmonary hypertension due to left heart disease when added to standard therapy.

  Recruiting at 18 sites Pulnovo Medical, Inc. · Tucson, Arizona and 18 other locations · NCT07214376

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.